Karyopharm to Evaluate Low Dose Selinexor as a Potential Treatment for Hospitalized Patients with COVID-19
07 avr. 2020 07h00 HE
|
Karyopharm Therapeutics Inc.
− Company to Initiate a Global Randomized Clinical Trial to Treat Patients with COVID-19 − − XPO1 Inhibitors have Previously Demonstrated Preclinical Activity Against Numerous Respiratory Viruses...
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 avr. 2020 16h05 HE
|
Karyopharm Therapeutics Inc.
NEWTON, Mass., April 01, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an oncology-focused pharmaceutical company, today announced that the Compensation Committee of...
Karyopharm Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
17 mars 2020 16h05 HE
|
Karyopharm Therapeutics Inc.
NEWTON, Mass., March 17, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an oncology-focused pharmaceutical company, today announced that the Compensation Committee of...
Karyopharm Expands Executive Leadership Team with the Appointment of John Demaree as Chief Commercial Officer
12 mars 2020 07h00 HE
|
Karyopharm Therapeutics Inc.
NEWTON, Mass., March 12, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced the appointment of John Demaree as Chief...
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09 mars 2020 16h05 HE
|
Karyopharm Therapeutics Inc.
NEWTON, Mass., March 09, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an oncology-focused pharmaceutical company, today announced that the Compensation Committee of...
Karyopharm Therapeutics Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
06 mars 2020 16h05 HE
|
Karyopharm Therapeutics Inc.
NEWTON, Mass., March 06, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced the closing of its previously announced...
Karyopharm Therapeutics Announces Pricing of Public Offering of Common Stock
03 mars 2020 18h36 HE
|
Karyopharm Therapeutics Inc.
NEWTON, Mass., March 03, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced the pricing of its previously announced...
Karyopharm Therapeutics Announces Proposed Public Offering of Common Stock
02 mars 2020 16h01 HE
|
Karyopharm Therapeutics Inc.
NEWTON, Mass., March 02, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced the commencement of a registered...
Karyopharm Announces Phase 3 BOSTON Study Meets Primary Endpoint with Significant Increase in Progression-Free Survival in Patients with Multiple Myeloma Following One to Three Prior Lines of Therapy
02 mars 2020 07h00 HE
|
Karyopharm Therapeutics Inc.
− Combination of Once-Weekly XPOVIO® (selinexor), Once-Weekly Velcade® (bortezomib) plus Dexamethasone (SVd) Results in Statistically Significant Reduction in the Risk of Disease Progression or Death...
Karyopharm Appoints Richard Paulson to its Board of Directors
28 févr. 2020 07h00 HE
|
Karyopharm Therapeutics Inc.
NEWTON, Mass., Feb. 28, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced the appointment of Richard Paulson to its...